Novo Nordisk addresses off-label Ozempic use as it grapples with multiple shortages
On the heels of Wegovy supply troubles, Novo Nordisk is reporting a shortage of its diabetes treatment Ozempic which contains the same active ingredient, semaglutide …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
